Literature DB >> 23489000

Spider peptide toxins as leads for drug development.

Pierre Escoubas1, Frank Bosmans.   

Abstract

Venomous animals use a highly complex cocktails of proteins, peptides and small molecules to subdue and kill their prey. As such, venoms represent highly valuable combinatorial peptide libraries, displaying an extensive range of pharmacological activities, honed by natural selection. Modern analytical technologies enable us to take full advantage of this vast pharmacological cornucopia in the hunt for novel drug leads. Spider venoms represent a resource of several million peptides, which selectively target specific subtypes of ion channels. Structure-function studies of spider toxins are leading not only to the discovery of novel molecules, but also to novel therapeutic routes for cardiovascular diseases, cancer, neuromuscular diseases, pain and to a variety of other pathological conditions. This review presents an overview of spider peptide toxins as candidates for therapeutics and focuses on their applications in the discovery of novel mechanisms of analgesia.

Entities:  

Year:  2007        PMID: 23489000     DOI: 10.1517/17460441.2.6.823

Source DB:  PubMed          Journal:  Expert Opin Drug Discov        ISSN: 1746-0441            Impact factor:   6.098


  11 in total

Review 1.  Sodium channel blockers for the treatment of neuropathic pain.

Authors:  Anindya Bhattacharya; Alan D Wickenden; Sandra R Chaplan
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

2.  Seven novel modulators of the analgesic target NaV 1.7 uncovered using a high-throughput venom-based discovery approach.

Authors:  Julie K Klint; Jennifer J Smith; Irina Vetter; Darshani B Rupasinghe; Sing Yan Er; Sebastian Senff; Volker Herzig; Mehdi Mobli; Richard J Lewis; Frank Bosmans; Glenn F King
Journal:  Br J Pharmacol       Date:  2015-03-04       Impact factor: 8.739

3.  Successful refolding and NMR structure of rMagi3: A disulfide-rich insecticidal spider toxin.

Authors:  Gustavo Titaux-Delgado; Elisa Carrillo; Angeles Mendoza; Marlen Mayorga-Flores; Fátima C Escobedo-González; Patricia Cano-Sánchez; Estuardo López-Vera; Gerardo Corzo; Federico Del Rio-Portilla
Journal:  Protein Sci       Date:  2018-01-03       Impact factor: 6.725

Review 4.  Spider-venom peptides as therapeutics.

Authors:  Natalie J Saez; Sebastian Senff; Jonas E Jensen; Sing Yan Er; Volker Herzig; Lachlan D Rash; Glenn F King
Journal:  Toxins (Basel)       Date:  2010-12-20       Impact factor: 4.546

5.  Lengths of the C-Terminus and Interconnecting Loops Impact Stability of Spider-Derived Gating Modifier Toxins.

Authors:  Akello J Agwa; Yen-Hua Huang; David J Craik; Sónia T Henriques; Christina I Schroeder
Journal:  Toxins (Basel)       Date:  2017-08-12       Impact factor: 4.546

Review 6.  Animal Toxins as Therapeutic Tools to Treat Neurodegenerative Diseases.

Authors:  Jessica M de Souza; Bruno D C Goncalves; Marcus V Gomez; Luciene B Vieira; Fabiola M Ribeiro
Journal:  Front Pharmacol       Date:  2018-02-23       Impact factor: 5.810

Review 7.  From Marine Venoms to Drugs: Efficiently Supported by a Combination of Transcriptomics and Proteomics.

Authors:  Bing Xie; Yu Huang; Kate Baumann; Bryan Grieg Fry; Qiong Shi
Journal:  Mar Drugs       Date:  2017-03-30       Impact factor: 5.118

8.  Insect-Active Toxins with Promiscuous Pharmacology from the African Theraphosid Spider Monocentropus balfouri.

Authors:  Jennifer J Smith; Volker Herzig; Maria P Ikonomopoulou; Sławomir Dziemborowicz; Frank Bosmans; Graham M Nicholson; Glenn F King
Journal:  Toxins (Basel)       Date:  2017-05-05       Impact factor: 4.546

9.  The lethal toxin from Australian funnel-web spiders is encoded by an intronless gene.

Authors:  Sandy Steffany Pineda; David Wilson; John S Mattick; Glenn F King
Journal:  PLoS One       Date:  2012-08-22       Impact factor: 3.240

10.  A new theraphosid spider toxin causes early insect cell death by necrosis when expressed in vitro during recombinant baculovirus infection.

Authors:  Daniel Mendes Pereira Ardisson-Araújo; Fabrício Da Silva Morgado; Elisabeth Ferroni Schwartz; Gerardo Corzo; Bergmann Morais Ribeiro
Journal:  PLoS One       Date:  2013-12-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.